Vancouver company in fight to identify COVID-19 variant-killing vaccine
April 13, 2021
Source: VancouverSun.com
Messenger RNA vaccines (Pfizer and Moderna) are the most effective of the suite of vaccines being made globally and are the most commonly used in B.C.
A Vancouver company is studying COVID-19 vaccine candidates that could be effective in controlling mutant strains now taking over the world.
According to a news release, Eyam Vaccines and Immunotherapeutics has started preclinical studies on the “efficacy of unique COVID-19 vaccine candidates that target SARS-CoV-2 variants.”
The study is part of a joint venture licensing agreement struck last November with the University of B.C. to “develop several propriety COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform.”
Messenger RNA vaccines (Pfizer and Moderna) are the most effective of the suite of vaccines being made globally and are the most commonly used in B.C.
The joint venture used mRNA candidates identified by leading Canadian immunologist and company chairman Dr. Wilfred Jeffries.
“New vaccines that are able to be effective for multiple variants are needed to address the emerging SARS-CoV-2 variants and this is the focus of our current preclinical work,” said Eyam CEO Ryan M. Thomas. “Overall, the commencement of preclinical studies represents a key milestone in our research program that will establish Eyam as a worldwide leader in the creation and commercial development of vaccines.”
Full story: https://vancouversun.com/news/local-news/vancouver-company-in-fight-to-identify-covid-19-variant-killing-vaccine
Vancouver company in fight to identify COVID-19 variant-killing vaccine
April 13, 2021
Source: VancouverSun.com
Messenger RNA vaccines (Pfizer and Moderna) are the most effective of the suite of vaccines being made globally and are the most commonly used in B.C.
A Vancouver company is studying COVID-19 vaccine candidates that could be effective in controlling mutant strains now taking over the world.
According to a news release, Eyam Vaccines and Immunotherapeutics has started preclinical studies on the “efficacy of unique COVID-19 vaccine candidates that target SARS-CoV-2 variants.”
The study is part of a joint venture licensing agreement struck last November with the University of B.C. to “develop several propriety COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform.”
Messenger RNA vaccines (Pfizer and Moderna) are the most effective of the suite of vaccines being made globally and are the most commonly used in B.C.
The joint venture used mRNA candidates identified by leading Canadian immunologist and company chairman Dr. Wilfred Jeffries.
“New vaccines that are able to be effective for multiple variants are needed to address the emerging SARS-CoV-2 variants and this is the focus of our current preclinical work,” said Eyam CEO Ryan M. Thomas. “Overall, the commencement of preclinical studies represents a key milestone in our research program that will establish Eyam as a worldwide leader in the creation and commercial development of vaccines.”
Full story: https://vancouversun.com/news/local-news/vancouver-company-in-fight-to-identify-covid-19-variant-killing-vaccine
